Ignite Creation Date:
2024-10-25 @ 7:47 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06598527
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-14
Brief Title:
Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumav Plus Platinum-based Chemotherapy As Neoadjuvant Therapy in Patients with Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer a Phase Ⅲ Randomized Multicenter Prospective Study
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumav Plus Platinum-based Chemotherapy As Neoadjuvant Therapy in Patients with Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer a Phase Ⅲ Randomized Multicenter Prospective Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SACTION2401
Brief Summary:
The goal of this clinical trial is to compare the efficacy and safety of neoadjuvant Stereotactic Body Radiotherapy SBRT combined with immunochemotherapy versus neoadjuvant immunochemotherapy The main questions it aims to answer are
Dose SBRT combined with immunochemotherapy improve event-free survival Is SBRT combined with immunochemotherapy safe enough
Participants will
Receive neoadjuvant SBRT combined with immunochemotherapy or neoadjuvant immunochemotherapy
Tumor assessment will be performed prior to surgery Surgery will be performed within 4 to 6 weeks 7 days after completion of the last cycle of immunochemotherapy
Dose SBRT combined with immunochemotherapy improve event-free survival Is SBRT combined with immunochemotherapy safe enough
Participants will
Receive neoadjuvant SBRT combined with immunochemotherapy or neoadjuvant immunochemotherapy
Tumor assessment will be performed prior to surgery Surgery will be performed within 4 to 6 weeks 7 days after completion of the last cycle of immunochemotherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None